MX2014009892A - Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas. - Google Patents
Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.Info
- Publication number
- MX2014009892A MX2014009892A MX2014009892A MX2014009892A MX2014009892A MX 2014009892 A MX2014009892 A MX 2014009892A MX 2014009892 A MX2014009892 A MX 2014009892A MX 2014009892 A MX2014009892 A MX 2014009892A MX 2014009892 A MX2014009892 A MX 2014009892A
- Authority
- MX
- Mexico
- Prior art keywords
- pazopanib
- combinations
- histone deacetylase
- deacetylase inhibitor
- salt
- Prior art date
Links
- 239000003798 L01XE11 - Pazopanib Substances 0.000 title abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000639 pazopanib Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600491P | 2012-02-17 | 2012-02-17 | |
| US201261602544P | 2012-02-23 | 2012-02-23 | |
| PCT/US2013/026462 WO2013123413A2 (en) | 2012-02-17 | 2013-02-15 | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014009892A true MX2014009892A (es) | 2015-02-12 |
Family
ID=48984895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009892A MX2014009892A (es) | 2012-02-17 | 2013-02-15 | Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150335609A1 (enExample) |
| EP (1) | EP2814493A4 (enExample) |
| JP (1) | JP2015507020A (enExample) |
| KR (1) | KR20140129164A (enExample) |
| CN (1) | CN104244952A (enExample) |
| AU (1) | AU2013221298A1 (enExample) |
| CA (1) | CA2864736A1 (enExample) |
| HK (1) | HK1204998A1 (enExample) |
| MX (1) | MX2014009892A (enExample) |
| RU (1) | RU2014137190A (enExample) |
| SG (1) | SG11201404888SA (enExample) |
| WO (1) | WO2013123413A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3079699A4 (en) * | 2013-12-11 | 2017-07-19 | Glaxosmithkline LLC | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| AU2016296905B2 (en) * | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| WO2017053823A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
| US11229657B2 (en) * | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
| JP7227777B2 (ja) * | 2019-02-04 | 2023-02-22 | キヤノン株式会社 | 撮像装置 |
| KR20220018727A (ko) | 2020-08-07 | 2022-02-15 | 계명대학교 산학협력단 | 파조파닙 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
| US20240075031A1 (en) * | 2020-12-07 | 2024-03-07 | Hht Foundation International, Inc. | Method of treating hereditary hemorrhagic telangiectasia using pazopanib |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004230889B2 (en) * | 2003-04-07 | 2008-03-13 | Pharmacyclics Llc | Hydroxamates as therapeutic agents |
| WO2005105094A2 (en) * | 2004-04-16 | 2005-11-10 | Smithkline Beecham Corporation | Cancer treatment method |
| DE602006020611D1 (de) * | 2005-11-29 | 2011-04-21 | Glaxosmithkline Llc | Krebsbehandlungsverfahren |
| CN102245184A (zh) * | 2008-12-15 | 2011-11-16 | 伊莱利利公司 | 用于治疗癌症的恩扎妥林 |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
| SG191926A1 (en) * | 2011-01-26 | 2013-08-30 | Glaxosmithkline Intellectual Property Ltd | Combinations |
-
2013
- 2013-02-15 US US14/377,380 patent/US20150335609A1/en not_active Abandoned
- 2013-02-15 KR KR1020147025547A patent/KR20140129164A/ko not_active Withdrawn
- 2013-02-15 MX MX2014009892A patent/MX2014009892A/es unknown
- 2013-02-15 CN CN201380020595.0A patent/CN104244952A/zh active Pending
- 2013-02-15 EP EP13748860.7A patent/EP2814493A4/en not_active Withdrawn
- 2013-02-15 SG SG11201404888SA patent/SG11201404888SA/en unknown
- 2013-02-15 WO PCT/US2013/026462 patent/WO2013123413A2/en not_active Ceased
- 2013-02-15 JP JP2014557835A patent/JP2015507020A/ja active Pending
- 2013-02-15 HK HK15105968.0A patent/HK1204998A1/xx unknown
- 2013-02-15 RU RU2014137190A patent/RU2014137190A/ru not_active Application Discontinuation
- 2013-02-15 CA CA2864736A patent/CA2864736A1/en not_active Abandoned
- 2013-02-15 AU AU2013221298A patent/AU2013221298A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013221298A1 (en) | 2014-08-28 |
| CA2864736A1 (en) | 2013-08-22 |
| SG11201404888SA (en) | 2014-09-26 |
| EP2814493A4 (en) | 2015-07-22 |
| CN104244952A (zh) | 2014-12-24 |
| EP2814493A2 (en) | 2014-12-24 |
| RU2014137190A (ru) | 2016-04-10 |
| US20150335609A1 (en) | 2015-11-26 |
| HK1204998A1 (en) | 2015-12-11 |
| JP2015507020A (ja) | 2015-03-05 |
| WO2013123413A2 (en) | 2013-08-22 |
| KR20140129164A (ko) | 2014-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365393B (es) | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| IN2014DN10670A (enExample) | ||
| HK1211475A1 (en) | Combination therapy | |
| PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
| MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| MX2014009892A (es) | Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas. | |
| PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| PH12012501550A1 (en) | Modified tuberculosis antigens | |
| PH12016501015A1 (en) | Combinations of histone deacetylase inhibitors and immunomodulatory drugs | |
| AU2013337247A8 (en) | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | |
| EP2771321A4 (en) | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| PT2991982T (pt) | Novos compostos para inibidores seletivos de histonadesacetilase e composição farmacêutica que os compreende | |
| MX2013009764A (es) | Moduladores de receptores canabinoides. | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| EP3049389A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP3125944A4 (en) | Methods and compositions for administering an active agent to the pleura of a patient | |
| PH12015500069A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| EP3049077A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2014145314A3 (en) | Methods and compositions for gamma-glutamyl cycle modulation |